<DOC>
	<DOCNO>NCT01723579</DOCNO>
	<brief_summary>This study investigate efficacy safety monophasic combine oral contraceptive ( COC ) contain 2.5 mg NOMAC 1.5 mg E2 healthy fertile Indian woman .</brief_summary>
	<brief_title>Efficacy Safety Oral NOMAC-E2 Indian Women ( P07057/MK-8175A-017 )</brief_title>
	<detailed_description />
	<mesh_term>Megestrol</mesh_term>
	<mesh_term>Estradiol 3-benzoate</mesh_term>
	<mesh_term>Estradiol 17 beta-cypionate</mesh_term>
	<mesh_term>Estradiol valerate</mesh_term>
	<mesh_term>Contraceptive Agents</mesh_term>
	<mesh_term>Contraceptives , Oral</mesh_term>
	<mesh_term>Estradiol</mesh_term>
	<mesh_term>Polyestradiol phosphate</mesh_term>
	<mesh_term>Contraceptives , Oral , Combined</mesh_term>
	<criteria>Sexually active risk pregnancy Of Indian descent , bear India , never emigrate India , Indian home address Body mass index ( BMI ) ≥17 ≤35 kg/m^2 Presence history venous arterial thrombotic/thromboembolic event cerebrovascular accident Presence history prodromi thrombosis History migraine focal neurological symptom Diabetes mellitus vascular involvement Presence severe multiple risk factor ( ) venous arterial thrombosis Severe hypertension Severe dyslipoproteinemia Presence history pancreatitis associate severe hypertriglyceridemia Presence history severe hepatic disease Undiagnosed vaginal bleeding Known suspect pregnancy Currently breastfeed breastfeed within 2 month start trial medication Investigational drug use participation another clinical trial within 2 month sign Informed Consent Form current trial</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>August 2015</verification_date>
</DOC>